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Abstract
Caesalpinia sappan L. and Ficus septica Burm. f known as a potential plant with wide variety of
medicinal properties, including anticancer. Present study was aimed to explore cytotoxic effect of sappan
wood (ECS) and awar­awar leaves (EFS), and its combination with doxorubicin (dox) on MCF­7 cells
focusing on cell cycle progression and apoptosis induction. The result of MTT assay showed that single
treatment of ECS and dox performed cytotoxic effect with the IC50 value of 32 µg/mL and 6 µM respectively,
while EFS performed low cytotoxic effect with the IC50 value of 282 µg/mL. The combination of ECS
with EFS and doxorubicin showed synergistic cytotoxic effect. Flow cytometry analysis revealed that
combination of ECS (16 µg/mL) with EFS (8 µg/mL) and doxorubicin (2 µM) induced apoptosis, and
cell accumulation at sub­G1 and G2/M phases. Immunoblotting assay confirmed the apoptosis induction
of this combination through increasing of cleavage of PARP­1. Based on these results, the synergistic
cytotoxic effect of this combination was through G2/M phase accumulation and apoptosis induction
and potentially to be developed as co­chemotherapeutic agent.
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Introduction
Cancer is a malignant disease, marked
by uncontrolled cell proliferation and
spreading due to the aberration of many
regulatory growth system (Witsch et al., 2010).
Continuing proliferation and evading
apoptosis are the main factors of the
malignancy and mainly driven by cell cycle
progression with regardless of check point
control (Barnum and O’Connell, 2014). There
are many molecular event in these
physiological processes involving growth
signaling through MAP Kinases, cell cycle
regulatory proteins, and apoptosis regulation
(Santarpia et al., 2012). Most of the signal
regulatory system are the potential pivotal
targets of anti cancer agents. Therefore, the
development of combinatorial anti cancer
agents should consider to the main
predominantly molecular event in particular
cancers (Kummar et al., 2010).
To date, many molecules have been
identified to perform cytotoxic activity
targeted on (some) cancer markers such as
RTK (receptor tyrosine kinase) inhibitors
(Takeuchi and Ito, 2011), CDK (cyclin­
dependent kinase) inhibitors (Asghar et al.,
2015), NF­κB inhibitors (Hoesel and Schmid,
2013) and MMPs inhibitors (Cathcart et al.,
2015). Some of these active molecules are
natural plant origin. Meiyanto et al., 2012
noted that some citrus flavonoids perform
cytotoxic activities to some cancer cells through
inhibition of MAPK and NF­κB activation
(Meiyanto et al., 2012). Curcumin and other
compounds in turmeric are also reported to
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have anti cancer activity with some molecular
targets in cell cycle, apoptosis and cell
migration (Tuorkey, 2014). Some alkaloids
component also known to have cytotoxic
activity to some cancer cells, such as taxane
alkaloids and phenanthroindolizidine
(Chemler, 2009; Dumontet and Jordan, 2010).
Interestingly, the compounds composed in
the potential anticancer plants are believed
to contribute in the cytotoxic activity trough
different targets and may perform synergistic
effect.
Caesalpinia sappan L., commonly
known as sappan wood or secang in Indonesia,
is a plant of Leguminosae family, which has
been used widely as traditional medicine in
Asia (Nirmal et al., 2015). Chemical
investigation resulted that brazilin/brazilein
is the major compound of sappan wood
(Mekala and Radha, 2015). Brazilin is easily
oxidized to produce brazilein by air and light.
Both brazilin and brazilein responsible for
various biological activities of sappan wood,
including anticancer (Nirmal et al., 2015).
Ficus septica Burm. f. (awar­awar) ethanolic
leaves extract induced apoptosis and
downregulated Bcl2 expression on MCF­7
breast cancer cell lines (Sekti et al., 2010). The
n­hexane insoluble fraction and ethyl acetate
soluble fraction from leaves ethanolic extract
exhibited cytotoxic activity on T47D breast
cancer cell lines (Nugroho et al., 2011). The
hexane fraction combined with doxorubicin
showed synergistic activity on T47D (Nugroho
et al., 2013). In our previous study
(unpublished data) ethanolic extract of F.
septica leaves showed strong antimigration
activity on 4T1 cells by wound healing assay,
while sappan wood did not show the effect.
Therefore, we suggest the combination of
both extract might support each other with
different mechanism and resulting a
synergistic effect with lower dose of
doxorubicin. Thus, the combination might
be able to combat cancer through inhibition
of proliferation and also metastasis. This
present study was aimed to explore cytotoxic
effect of extract in MCF­7, the human breast
cancer cell line, and its combination effect
with doxorubicin. Furthermore, we also
investigated the possible combinatorial effect
of doxorubicin and the extract in cell cycle
progression and apoptosis induction.
Materials and Methods
Materials and extraction
Sappan wood (Caesalpinia sappan L.)
and awar (Ficus septica Burm. f.) leaves
obtained from Medicinal Plant and Traditional
Medicine Research and Development Center,
Tawangmangu, Central Java, Indonesia. They
were sliced, dried in 40°C, pulverized, and
extracted with ethanol 96% by maceration
method. The dried extract of sappan wood
(ECS) and ficus leaves (EFS), and also
doxorubicin (dox) were dissolved in DMSO
(Sigma),andfreshlydilutedinculturemedium
in several concentration before used.
Cell culture
MCF­7 cell lines were obtained from
ATCC HTB­22 and maintained in laboratory
of Molecular Biology, Medicinal Plant and
Traditional Medicine Research and
Development Centre, Ministry of Health,
Tawangmangu, Jawa Tengah, Indonesia.
Cells were cultured in Minimum Essential
Medium (MEM Gibco) containing 10% fetal
bovine serum/FBS (Gibco), 1% penicillin­
streptomycin (Gibco), and incubated in CO2
incubator 5% at 37°C.
Cytotoxic MTT assay
Approximately 1x104 MCF­7 cells/well
were seeded in 96­well plates and incubated
for 48 hours. Cells were treated with increasing
concentration of the extract or doxorubicin
either alone and in combination for 24 hours.
Cultured medium was removed and cells
were washed with PBS (Sigma). MTT 0.5
mg/ml in medium were added into each well
and incubated for 3–4 hours. MTT reaction
was stopped by the addition of 10% SDS in
0.01 N HCl, and incubated overnight in the
dark room. The absorbance was measured
using ELISA reader at λ 595 nm (Biorad).
Each treatment were carried out in triplicate,
and the absorbance data are provided as
percent viability compared to control cells
(untreated).
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Cell cycle and apoptosis induction by flow
cytometry assay
Approximately 5x105 MCF­7 cells/well
were cultured in 6­well plate and incubated
for 48 hours. Cells were then treated with the
extract and doxorubicin, either alone or
combination for 24 hours. Cells were harvested
with trypsin EDTA, washed with phosphate­
buffered saline (PBS), and centrifuged 500
rpm for 5 minutes. For apoptosis induction,
cells then incubated with annexin­V­FITC
and propidium iodide (BD Pharmingen) for
15 min in the dark, and analyzed by BD Accuri
C6 Flow cytometer. To determine cell cycle
distribution, cells were fixed with cold ethanol
70% for 30 minutes, washed with PBS, and
centrifuged 500 rpm for 5 minutes. Cells were
then resuspended in PBS containing 40 μg/ml
propidium iodide (Sigma), 20 μg/mL RNAse
(Roche) and 0.1% TritonX­114 (Sigma) for 15
minutes in the dark, and then subjected to
BD Accuri C6 flow cytometer.
Western Blot
Approximately 106 MCF­7 cells were
seeded in 10 cm tissue culture dish, and
incubated for 24 hours. Cell were treated with
the extract and doxorubicin, either alone or
combination for 24 hours. Protein was
extracted using Pro­prep (Intron
Biotechnology), then separated in 14%
acrylamide gel by SDS­PAGE electrophoresis.
After transferring to polyvinylidene fluoride
(PVDF) membrane, the membrane was
incubated overnight at 4°C with either the
rabbit monoclonal antibody of PARP­1 (Cell
Signaling D64E10) or mouse monoclonal
antibody of β­actin (Santa Cruz sc­47778).
After incubation with secondary antibody
anti­rabbit (Santa Cruz sc­2357) and anti­
mouse (Santa Cruz sc­516102) for 1 hour, the
protein bands were visualized using ECL
(Amersham) and detected by Luminograph.
The relative protein levels were calculated in
reference to the amount of β­actin protein.
Data analysis
To calculate the IC50 value from single
cytotoxicity assay, we plotted linear regression
of concentration and % cells viability using
Excel MS Office 2013. Combination treatment
was evaluated by calculating the Combination
Index (CI) value with Compusyn software.
The data obtained from flow cytometer was
analyzed using BD Accuri C6 software.
Results and Discussion
Results
Cell growth inhibitory effect by single treatment
of ECS, EFS, and dox
Our previous report noted that ethanolic
extract of ficus leaves and sappan wood
performed cytotoxic effect on T47D breast
cancer cells through cell cycle arrest and
apoptosis induction (Nugroho et al., 2015;
Nurzijah et al., 2012). In this report, we use
MCF7 breast cancer cells, a type of cancer cell
with caspase­3 mutation (Ghavami et al., 2009),
to explore the response of the cells to the
agents in single or in combination. The MCF­
7 cells treated with single ECS, EFS, and dox
showed cytotoxic effect in dose dependent
manner with the IC50 value of 32 µg/mL, 282
µg/mL, and 6 µM respectively (Figure 1).
Based on these results, we were then assessed
the combination effect of the extract and
doxorubicin in some series concentration on
MCF­7 cells.
Combinatorial effect of ECS, EFS, and dox on
MCF­7 cells viability
To evaluate the combinatorial effect
of these agents, we set the treatment with
the series concentration of each agent under
IC50 values. The result showed that the
increasing concentration of ECS 4, 5, 8, and
16 µg/ml and EFS 2, 3, 4, and 8 µg/ml in
combination was not followed by decreasing
cell viability, and resulted combination index
(CI) value 1.0–4.1. These CI values indicated
that combinational treatment of this extract
exhibited an additive and antagonistic
inhibitory effect on MCF­7 cells. Additive
effect was only achieved at the highest leaves
concentration used in this experiment.
However, when those extract combined with
doxorubicin 1.0, 1.5, and 2 µM, it resulted
synergistic effect. The only antagonistic effect
Haryanti et al. I.J. Biotech.
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was showed at the lowest concentration of
doxorubicin (0.5 µM) (Figure 2 and Table 1).
Cell cycle progression and apoptosis induction
The combination effect of dox and the
extract in cell growth inhibition could be as
the result of the modulation in physiological
process of the cells. To investigate the effect
of the combinatorial treatment in particular
physiological process of the cells we further
explored MCF­7 cell cycle progression and
cell death using flow cytometry. We were
selected one combination, ECS­EFS­
doxorubicin with the concentration of
16:8:2. Cell cycle histogram of the treatment
was presented in Figure 3. Single treatment
of dox 2 μM slightly induced G2/M arrested
(27.4%), while 16 μg/ml of ECS strongly
induced G2/M (43.1%) compared to cell
control (21.2%). Whereas, EFS did not affected
cell cycle profile. Interestingly, the
combination of ECS and EFS induced G2/M
arrested but lower than sappan alone (41.5%).
Moreover, the treatment of ECS, EFS and dox
combination increased cell population in
subG1 (7.1%) compared to untreated cells
(2.3%) and any single treatment. The G2/M
was still arrested with higher population
(32.8%) than that of doxorubicin treatment,
but lower than sappan alone (Figure 3).
To understand the cell death
mechanism in subG1 population, whether
synergistic combination was mediated
through apoptosis, we stained treated cells
with propidium iodide – annexin V and
subjected to flow cytometry (Figure 4). The
results showed the apoptotic population was
significantly increased in MCF­7 cells treated
by combination of ECS­EFS­dox (37.0%)
compared to untreated cells (2.7%) and single
I.J. Biotech.
Figure 1. Cytotoxic effect of ECS, EFS, and dox on MCF­7 cells. Cells were seeded in 96­well plate and treated
with ECS (A), EFS (B) or dox (C) for 24 hours with the series of concentration as indicated. Cells viability were
determined by MTT assay as described in methods, performed in triplicate, and represented as mean ± SD of %
cell viability. IC50 value was calculated using linier regression.
Table 1. Combination index (CI) and dose reduction index (DRI) values of doxorubicin in combination. CI < 1
indicates synergistic effect, CI = 1 indicates additive effects and CI > 1 indicates antagonistic effect (Chou, 2010).
­
8
CI value
8
­
2.9
Combo 3­3
Treatment
Concentration
% viability DRI (doxo)ECS EFS Dox
(µg/ml) (µg/ml) (µM)
Combo 2­1 4 2 ­ 84.4 + 9.2 1.10
Combo 2­2 5 3 ­ 88.1 + 6.5 4.10 ­
Combo 2­3 4 ­ 83.9 + 5.7 1.90
Combo 2­4 16 ­ 73.4 + 6.5 1.00
Combo 3­1 4 88.4 + 1.8 3.20 5.2
Combo 3­2 78.4 + 1.9 0.88
4 1.5 56.1 + 2.2 0.62
Combo 3­4 8 2 37.7 + 1.9 0.83
3.3
3.0
­
16
8
5
2
3 1
0.5
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treatment of dox (7.7%), ECS (17%), and EFS
(4.2%). The combination of ECS and EFS had
lower apoptotic cells (14.2%), but showed the
highest population on necrotic cells (4.6%).
To confirm apoptosis induction of the single
and combination treatment, we analyzed the
expression level of protein poly (ADP­ribose)
polymerase (PARP) by Western Blot.
Cleavage PARP­1, as indicator of apoptosis,
were shown in cells treated with single
doxorubicin and its combination with ECS
and EFS (Figure 4­H).
Discussion
Doxorubicin is one of the most active
chemotherapeutic agent and widely used for
I.J. Biotech.
Figure 2. Combinational cytotoxic effect of ECS, EFS and dox on MCF­7 cells. Cells were seeded in 96­well plate and
treated with ECS, EFS, or doxorubicin, either in single and combination. The concentration of ECS was 4, 5, 8, 16
µg/mL, EFS was 2, 3, 4, 8 µg/mL, and dox 0.5, 1.0, 1.5, 2.0 µM. The combination concentration of ECS and EFS was
4:2, 5:3, 8:4, and 16:8 µg/mL, while combination of ECS, EFS, and dox was 4:2:0.5, 5:3:1.0, 8:4:1.5, and 16:8:2.0. Cells
viability were performed in triplicate, and represented as mean ± SD.
DNA content
C
ou
nt
Figure 3. The effect of ECS, EFS, dox and their combination on cell cycle distribution. Cells were treated for 24 hours
and stained with PI reagent, each sample was subjected to flow cytometer. (A) Cell control, (B) dox 2 μM, (C) ECS
16 μg/ml, (D) EFS 8 μg/mL, (E) combination of ECS and EFS (F) combination of ECS, EFS, and dox.
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breast cancer treatment (Anampa et al., 2015).
Its application in chemotherapy is often
limited due to cardio toxicity risk and
resistance progression (Vejpongsa and Yeh,
2014). The development of doxorubicin
resistance in breast cancer is multifactorial
processes, mainly associated with wide and
diverse expression of drug­resistance genes,
and many other changes in genes responsible
for cell cycle, apoptosis and DNA repair
(AbuHammad and Zihlif, 2013). The
combination with a natural chemopreventive
agents is one of the promising strategy to
improve doxorubicin anticancer effectiveness
and reduce its toxicity (Ko and Moon, 2015).
Therefore, we investigated the modulatory
effect of ECS and EFS combined with
doxorubicin on cytotoxicity, cell cycle
progression and apoptosis induction in MCF­
7 human breast cancer cell line.
In this study, the MTT assay revealed
that MCF­7 cells viability was strongly
inhibited by single ECS, and also doxorubicin,
while the EFS exhibited low activity. We
further demonstrated MTT assay combination
of the extract and doxorubicin to obtain CI
value. The CI is widely accepted as the simplest
possible way to express pharmacologic drug
interaction for quantifying synergism or
antagonism. Synergism interaction will be
very useful to treat the dreadful diseases,
such as cancer. The main gains are the
achievement of synergistic therapeutic effect,
reduction of dose and toxicity, and also
minimize or delay drug resistance (Chou,
2010).
The synergistic inhibitory effect
achieved with the combination of doxorubicin
1.0, 1.5, and 2.0 µM (equal to 1/6, ¼ and 1/3
of IC50 respectively), with ECS (5, 8, 16
µg/mL) and EFS (3, 4, 8 µg/mL). The biggest
concentration of EFS was approximately 1/35
of IC50, based on its antimigration activity on
4T1 cells by wound healing method (data not
shown). Therefore, the combined extract may
lead to reduce of doxorubicin dose therapy
and furthermore minimizing its cardio
toxicity risk.
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Figure 4. The effect of ECS, EFS, dox and their combination on cell apoptosis. Cells were treated for 24 hours and
stained with PI reagent, each sample was subjected to flow cytometer. (A) Cell control, (B) dox 2 μM, (C) ECS 16
μg/ml, (D) EFS 8 μg/mL, (E) combination of ECS­EFS, (F) combination of ECS­EFS­dox. The diagram A­F divided
into 4 area, which showed distribution profiles of living cells (bottom­left), early apoptotic (bottom­right), late
apoptosis (upper­right), necrosis (upper­left) in various indicated treatment. Graphic (G) showed analysis results
for apoptosis induction for each treatment. (H) The effect of ECS, EFS, doxorubicin and their combination on cellular
expression levels of PARP­1 by Western blot. Protein β­actin was used as loading control.
Haryanti et al.
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Cell cycle regulation and apoptosis
induction play a critical role in cytotoxic
activity. The cell cycle is a tidy and tightly
regulated mechanism by which cell divide,
involving four phases namely G1, S
(synthesis), G2 and M (mitosis) (Deep and
Agarwal, 2008). The abrogation of cell cycle
checkpoints at critical time is expected to
target the errors of cell cycle regulation to
attain cancer cells specific cytotoxicity and to
make the tumor cell susceptible to apoptosis.
Currently, these agents are combined with
conventional chemotherapeutic agent to
overcome cell cycle mediated drug resistance
and to enhance cytotoxic efficacy (Kelley et
al., 2014). Doxorubicin modulates cell cycle
through G1 and G2 phases arrest, as the
result of its interaction with topoisomerase
II mediated DNA damage (Lal et al., 2010).
Our result confirmed that single treatment
of dox 2 µM and ECS 16 µg/ml induced cell
accumulation at G2/M phase. However, the
EFS 6 µg/ml alone did not show significant
changes in cell cycle profile. The
combination of dox with both ECS and EFS
enhanced cell accumulation at subG1,
compared to the untreated cells and each
single treatment. These results suggested
that EFS contributed to enhance the cytotoxic
effect of dox and ECS leading to cell death.
The cell cycle arrest depicted a
survival mechanism for the cancer cell to
repair its own damaged DNA. The
disruption of cell cycle checkpoints by
specific agent before completing DNA
repair, can activate the apoptotic pathway
leading to cell death (Carrassa, 2013). In our
study, the combination of doxorubicin with
both of the extract increased apoptotic and
necrotic cell induction, compared to
untreated cell and each single treatment.
Apoptosis induction was confirmed by
Western Blot analysis that showed PARP­1
cleavage in the treatment of single
doxorubicin, and its combination with ECS
and EFS.
PARP­1 can be cleaved by activated
caspases. The cleavage of PARP­1 will
inhibit uncleaved PARP­1 activity, thus
promote DNA damage response in multiple
pathway (Weaver and Yang, 2013). The
effect of PARP­1 inhibitors in apoptosis
induction, providing it as a promising target
in cancer therapy (Wang et al., 2012).
Apoptosis is one of cell death design,
showed an ordered and orchestrated
cellular process that occurs in physiological
condition and pathological of many
diseases. Apoptosis evasion plays a crucial
role in carcinogenesis, therefore it is
becoming as a popular target for cancer
treatment strategy (Wong, 2011). Also, the
aberrant cell cycle progression plays a
crucial role in cancer cell growth, thus
targeting the cell cycle have been regarded
as an ideal cancer treatment (Deep and
Agarwal, 2008).
Conclusions
Based on these findings, progressive
cytotoxicity effect of doxorubicin combined
with ECS and EFS extract inhibited MCF­7
cells growth through apoptosis induction
and cell cycle perturbation (G2/M arrest).
Therefore, the extract combination performs
potential natural sources to be developed
further as co­chemotherapeutic agent.
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